Akebia Therapeutics (AKBA)
NASDAQ:AKBA
Want to see AKBA full AI Analyst Report?
Total Valuation
Akebia Therapeutics has a market cap or net worth of $284.35M. The enterprise value is $120.79M.
Market Cap$284.35M
Enterprise Value$120.79M
Share Statistics
Akebia Therapeutics has 268,258,240 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding268,258,240
Owned by Insiders2.85%
Owned by Institutions2.73%
Financial Efficiency
Akebia Therapeutics’s return on equity (ROE) is -0.16 and return on invested capital (ROIC) is 9.26%.
Return on Equity (ROE)-0.16
Return on Assets (ROA)-0.01
Return on Invested Capital (ROIC)9.26%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee1.30M
Profits Per Employee-29.53K
Employee Count181
Asset Turnover0.63
Inventory Turnover2.53
Valuation Ratios
The current PE Ratio of Akebia Therapeutics is ―. Akebia Therapeutics’s PEG ratio is 0.83.
PE Ratio―
PS Ratio1.75
PB Ratio12.70
Price to Fair Value12.70
Price to FCF6.09
Price to Operating Cash Flow4.47
PEG Ratio0.83
Income Statement
In the last 12 months, Akebia Therapeutics had revenue of 236.20M and earned -5.34M in profits. Earnings per share was -0.02.
Revenue236.20M
Gross Profit196.73M
Operating Income23.50M
Pretax Income-3.72M
Net Income-5.34M
EBITDA21.73M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was 60.37M and capital expenditures -427.00K, giving a free cash flow of 60.01M billion.
Operating Cash Flow60.37M
Free Cash Flow60.01M
Free Cash Flow per Share0.22
Dividends & Yields
Akebia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.95
52-Week Price Change-65.41%
50-Day Moving Average1.37
200-Day Moving Average1.96
Relative Strength Index (RSI)28.08
Average Volume (3m)3.15M
Important Dates
Akebia Therapeutics upcoming earnings date is Jul 30, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Akebia Therapeutics as a current ratio of 1.13, with Debt / Equity ratio of 45.64%
Current Ratio1.13
Quick Ratio1.04
Debt to Market Cap0.52
Net Debt to EBITDA1.45
Interest Coverage Ratio0.97
Taxes
In the past 12 months, Akebia Therapeutics has paid 1.62M in taxes.
Income Tax1.62M
Effective Tax Rate-0.44
Enterprise Valuation
Akebia Therapeutics EV to EBITDA ratio is 20.50, with an EV/FCF ratio of 6.55.
EV to Sales1.89
EV to EBITDA20.50
EV to Free Cash Flow6.55
EV to Operating Cash Flow6.55
Balance Sheet
Akebia Therapeutics has $162.64M in cash and marketable securities with $12.49M in debt, giving a net cash position of $150.15M billion.
Cash & Marketable Securities$162.64M
Total Debt$12.49M
Net Cash$150.15M
Net Cash Per Share$0.56
Tangible Book Value Per Share-$0.10
Margins
Gross margin is 80.87%, with operating margin of 9.95%, and net profit margin of -2.26%.
Gross Margin80.87%
Operating Margin9.95%
Pretax Margin-1.58%
Net Profit Margin-2.26%
EBITDA Margin9.20%
EBIT Margin8.66%
Analyst Forecast
The average price target for Akebia Therapeutics is $4.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$4.67
Price Target Upside233.33% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast25.69%
EPS Growth Forecast64.06%